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Abstract: Chemotherapy-induced differentiation of immature myeloid progenitors, such as acute
myeloid leukemia (AML) cells or myeloid-derived suppressor cells (MDSCs), has remained a challenge
for the clinicians. Testing our imidazo[1,2-b]pyrazole-7-carboxamide derivative on HL-60 cells,
we obtained ERK phosphorylation as an early survival response to treatment followed by the increase
of the percentage of the Bcl-xlbright and pAktbright cells. Following the induction of Vav1 and the
AP-1 complex, a driver of cellular differentiation, FOS, JUN, JUNB, and JUND were elevated on
a concentration and time-dependent manner. As a proof of granulocytic differentiation, the cells
remained non-adherent, the expression of CD33 decreased; the granularity, CD11b expression,
and MPO activity of HL-60 cells increased upon treatment. Finally, viability of HL-60 cells
was hampered shown by the depolarization of mitochondria, activation of caspase-3, cleavage of
Z-DEVD-aLUC, appearance of the sub-G1 population, and the leakage of the lactate-dehydrogenase
into the supernatant. We confirmed the differentiating effect of our drug candidate on human
patient-derived AML cells shown by the increase of CD11b and decrease of CD33+, CD7+, CD206+,
and CD38bright cells followed apoptosis (IC50: 80 nM) after treatment ex vivo. Our compound reduced
both CD11b+/Ly6C+ and CD11b+/Ly6G+ splenic MDSCs from the murine 4T1 breast cancer model
ex vivo.
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1. Introduction
Myeloproliferative neoplasms (MPNs) and myelodysplastic syndromes (MDS) are diseases
of the hematopoietic stem cells in the bone marrow (BM) where an excess of immature cells is
produced, which can frequently evolve to different myeloid leukemias [1,2]. The group of myeloid
cells have been determined by the WHO classification, including granulocytic (neutrophil, eosinophil,
and basophil), monocytic/macrophage, erythroid, megakaryocytic, and mast cell lineages [1]. The acute
myelogenous/myeloid leukemia (AML) is the most common acute leukemia in adults with the incidence
of 4.3 in the USA per 100,000 person-years. The AML has the shortest survival among leukemias
(in 5 year survival = 24%), especially in the elderly (at age ≥ 65 years) the AML predicts the worst
overall median survival (2.67 months) [3]. The AMLs represent a group of heterogeneous forms of
myeloid malignancies with diverse genetic abnormalities and different stages of myeloid differentiation.
The AMLs originate from myeloid stem cells or myeloid blasts halted in an immature state during
hematopoiesis where more than 20% of blasts can be detected in the BM which counteracts with the
production of normal blood cells [4].
Current treatment of these myeloid malignancies (MPNs, MDS, and AML) is different. There is
no available curative treatment for any type of MPNs. The aims of therapies in MPNs are to
limit the severity of symptoms to avoid thrombohemorrhagic complications, and limit anemia and
splenomegaly [5,6]. The aims of the therapies in the case of MDS are also to diminish the symptoms,
improve the quality of life and decrease progression to AML. Allogeneic stem cell transplantation
can be considered under the age of 45 in high risk patients. Supporting cares are blood transfusion
and the administration of erythropoietin. Chemotherapy for MDS is performed by the administration
of 5-azacytidin, decitabine, and lenalidomide [7]. The treatment of AML mostly relies on high dose
chemotherapy. Hematopoietic stem cell transplantation is recommended for younger patients with
high risk, therapy refractory or relapsed disease with available HLA-matched donors. The aim of the
first line treatment, called induction phase therapy, is to eradicate the leukemic clone and achieve
complete remission. The second phase is called consolidation therapy, which helps maintaining
complete remission by eliminating minimal residual disease. During induction therapy cytarabine and
anthracycline are given, except subtype M3. The overall survival of AML remained poor, however novel
therapies have been approved by the FDA, which are CPX-351 (daunorubicin/cytarabine), enasidenib
(IDH2 inhibitor), midostaurin (FLT3 inhibitor), and gemtuzumab ozogamicin antibody–drug conjugate
(GO) targeting CD33+ cells [8]. The acute promyelocytic leukemia (APL; the AML subtype M3) is
treated mainly by all-trans retinoic acid (ATRA) and arsenic trioxide [9,10]. The prototype model used
in our study was the human cell line, HL-60 promyeloblasts isolated form a female leukemia patient in
1977 presumed as acute promyelocytic leukemia (APL), but later reclassified to acute myeloblastic
leukemia FAB-M2 because of the absence of t(15:17) translocation [11–13]. The lineage-uncommitted
HL-60 cell line is suitable to model patient-derived samples responsive to differentiation induced
chemotherapy. It has been shown that treatment of immature HL-60 cells by ATRA or DMSO resulted
in granulocytic differentiation [14,15]. The phorbol ester 12-O-tetradecanoylphorbol 13-acetate (TPA),
or 1,25-dihydroxyvitamin D3, induced the differentiation of HL-60 cells into a macrophage like adherent
phenotype [16,17]. However, ATRA failed the clinical management of AML lacking the PML–RARα
target fusion protein frequent in APL [18,19].
Chemotherapy-induced differentiation has been addressed in the late 1970s and still remained
a therapeutic challenge to treat immature myeloid leukemias with high need for novel effective
compounds [19]. We have previously synthetized a 67 member imidazo[1,2-b]pyrazole-7-carboxamide
compound library with potent cytotoxic effect on HL-60 cells [20], and optimization of structure–activity
relationship (SAR) resulted in the design of seven more active compounds [21]. These agents induced
apoptosis in nanomolar range on HL-60 cells, but the way of action was not revealed. In order to
explore the mechanism of action, our imidazo[1,2-b]pyrazole-7-carboxamide derivative, published
earlier as DU325 [21], was further investigated to elicit its cytotoxic effect on human HL-60 and primary
patient-derived AML cells.
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Another pathologic condition of myeloid expansion is the ”emergency” granulo-monocytopoiesis
in most of the solid malignancies in which, an army of immature myeloid cells leave the bone
marrow, called monocytic and granulocytic myeloid-derived suppressor cells (MDSCs) [22]. We have
previously reviewed this myeloid infiltrate in solid tumors, how is orchestrated by MDSCs [23].
The murine MDSCs are CD11b+ and Gr1+ heterogeneous populations of immature myeloid cells
developed from bone marrow common myeloid progenitors [24], MDSCs are precursors of granulocytes,
monocytes, macrophages, and dendritic cells. MDSCs are classified as Ly6C+ monocytic (M-MDSC)
and Ly6G+ granulocytic (G-MDSC) subpopulations in mice [25]. Due to the lack of Gr1 homologue in
humans, the identification of MDSCs is not so evident, human MDSCs consist of phenotypically more
heterogeneous population of myeloid cell precursors, briefly M-MDSC (CD11b+, HLA-DR−/low,CD33+,
CD14+, CD15−), G-MDSC (CD11b+,HLA-DR−/low, CD33+, CD15+ or CD66b+), or the less well defined
more immature MDSCs (CD14−, CD15−) [26,27]. In contrast to AML, MDSCs are not malignant cells,
but promote tumor growth by several mechanisms including their inherent immunosuppressive activity,
promotion of neoangiogenesis, mediation of epithelial-mesenchymal transition and altering cancer cell
metabolism. These protumoral functions of MDSCs offer a myriad of potential anticancer therapeutic
targets that we have previously reviewed [28]. We have recently reported the immunomodulatory
effect of cisplatin via the suppression of splenic MDSCs in the 4T1 murine breast cancer model [29].
Because MDSCs are immature myeloid cells with immunosuppressive capacity, differentiation into
mature myeloid cells, thereby restoration of antitumor T-cell immunity has been proven a promising
therapeutic strategy [30,31]. Three agents—the calcitriol receptor agonist 1,25-dihydroxyvitamin D3 (vitamin
D3) [32,33], the retinoic acid receptor agonist ATRA [34], and TLR7/8 agonist resiquimod [35]—have been
verified to mature MDSCs and reduce tumor nursing condition of immunosuppression [28].
Based on these findings we addressed to investigate the cytotoxic and differentiating effect of our
imidazo[1,2-b]pyrazole-7-carboxamide derivative on splenic immature myeloid cells, both on M- and
G-MDSCs accumulated in 4T1 breast cancer-bearing mice.
2. Results
2.1. DU325 Drives Survival Pathways as an Early Response to Treatment in HL-60 Cells
In order to study the underlying mechanism of action of our recently developed drug candidate,
DU325 with anti-leukemic effect [21], the prototype model of human acute myeloblastic leukemia,
the HL-60 cells, were treated and assayed. HL-60 cells have been widely used earlier to test
differentiation induced chemotherapy [36–38]. We have previously observed the asynchronous
response of HL-60 cells in terms of morphology treated with DU325 and decided to obtain single cell
protein expression data in a subpopulation of cells (bright) by using flow cytometry. We investigated
ERK1/2 (extracellular-signal regulated kinases, alternatively MAPK mitogen-activated protein kinases)
phosphorylation at Thr202/Tyr204 because ERK has been reported to be involved in myeloid
differentiation of HL-60 cells [36,39,40]. The short-term treatment (2 h) of HL-60 cells with 1 µM and 5
µM DU325 induced 13 ± 1.89 % (p < 0.001) and 20 ± 1.49 % (p < 0.001) of pERKbright positive cells,
respectively (Figure 1A and Figure S1A). The accumulation of Bcl-xl has been reported to suppress
apoptosis during monocytic differentiation process of HL-60 cells via ERK dependent fashion [41,42].
Indeed, we could detect the increase of the percentage of Bcl-xlbright cells with a peak at 50.3 ± 5.5 %
(p < 0.001) upon 1 µM DU325 treatment (Figure 1B and Figure S1B). Another factor, the Akt (also known
as Protein kinase B or RAC-alpha serine/threonine-protein kinase) that has been reported regulating
survival during the differentiation of myeloid cells via NF-κB-dependent induction of Bcl-xl [43].
The percentage of cells with high pAkt (Ser473) was detected 20 ± 4 % (p < 0.001) after incubation with
200 nM DU325 (Figure 1C and Figure S1C). The higher concentrations of DU325 caused a decline in the
percentage of Bcl-xlbright and pAktbright cells probably because of the previously reported apoptotic
effect [21].
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Figure 1. Drug candidate DU325 drives survival pathways as an early response to treatment in
HL-60 cells. Using flow cytometry, we obtained ERK phosphorylation (pERK1/2, Thr202/Tyr204) (A)
as an early response to DU325 stimulation followed by the increase of the percentage of the Bcl-xl
(B) and pAkt (Ser473) bright cells (C). Cells were treated as described in the Materials and Methods
Section 4.12.4 for 2 h to assess ERK1/2 phosphorylation, and for 24 h to assess the upregulation of the
anti-apoptotic Bcl-xlbright and pAktbright cells. Data are shown as arithmetic mean values ± standard
deviation from triplicate experiments. Statistical significance was calculated in relation to untreated
cells and set to ** p < 0.01, *** p < 0.001.
2.2. DU325 Induces Differentiation of HL-60 Cells
One of the master regulators of myeloid differentiation is Vav1, the hematopoietic cell-specific
form of Vav proteins. Vav1 could act via several mechanisms, such as its guanine exchange factor (GEF)
activity of GDP/GTP [44], regulating cell motility via cytoskeletal reorganization or modulation of gene
expression [45]. The GEF activity of Vav1 is dependent on phosphorylation by either Syk, Zap70, Src,
or JNK kinases [37], but Vav1 can have a direct effect on the transcriptional machinery as a component
of the transcriptionally active complex or interacting with transcription factors, ribonucleoprotein
complexes independent of its GEF activity [46–48]. We could detect the accumulation of Vav1 in
whole cell lysates (Figure 2A and Figure S2A) and in the nuclei (Figure 2B and Figure S2B) of
HL-60 cells with 50% increase treated with 200 nM or 1 µM DU325, respectively, as early as 24 h.
Additionally, the increase of the phosphorylation of Vav1 on Tyr-174 residues was detected in the
whole cell lysates (Figure 2C) and in the nuclei (Figure 2D).
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Figure 2. DU325 affects both cellular and nuclear levels of Vav1 in HL-60 cells. Relative levels of
Vav1 in whole cells (A) and in the nuclei (B), and p174-Vav1 (Tyr174) in whole cells (C) and in the nuclei
(D) from HL-60 cells grown in the presence of DU325 at the reported concentrations for the indicated
times (h). Cells were assayed as described in the Materials and Methods Section 4.10. The values are
deduced from the densitometry of immunochemical bands normalized with β-Tubulin for whole cells
or with Lamin B for the nuclei as internal controls of loaded proteins (Figure S2). Data are shown as
arithmetic mean values ± standard deviation from triplicate experiments. Statistical significance was
calculated in relation to untreated cells and set to * p < 0.05, ** p < 0.01.
Mollinedo et al. published that differentiation of HL-60 cells upon stimulation with
1 alpha,25-dihydroxyvitamin D3 required the expression of transcription factor activator protein 1
(AP-1) family members, multiple protein complexes such as FOS and JUN, JUNB, or JUND [49]. The FOS
can heterodimerize with JUN members, while the JUN proteins can either homo- or heterodimerize
to bind to the target sequences of transcriptionally active DNA elements [50]. We investigated the
expression of the AP-1 subunits because both ERK1/2 [51,52] and Vav1 can play a role in the activation
of the AP-1 pathway [53,54]. We observed a gradual increase in the expression of FOS (4-times,
p < 0.001) (Figure 3A), JUN (4-times, p < 0.01) (Figure 3B), and JUND (2.5× times, p < 0.01) (Figure 3D)
after 6 h treatment with 200 nM DU325, while JUNB elevated by 40 nM DU325 after 12 h (1.8× times,
p < 0.01) (Figure 3C).
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Figure 3. The expression of the members of the AP-1 TF (TF = transcription factor) complex, a driver of
cellular differentiation, FOS (A), JUN (B), JUNB (C), and JUND (D), was elevated in a concentration and
time dependent manner detected by qRT-PCR. Cells were assayed as described in the Materials and
Methods Section 4.9. Data are shown as arithmetic mean values ± standard deviation from triplicate
experiments. Statistical significance was calculated in relation to untreated cells and set to * p < 0.05, **
p < 0.01, *** p < 0.001.
The differentiation of HL-60 immature acute myeloid leukemia cells has been reported with
decrease in the expression of early hematopoietic progenitor marker CD33 (Sialic Acid-Binding Ig-Like
Lectin 3) and an increase of matured myeloid marker CD11b [55,56]. Next, we investigated the
expression of these markers and showed a concentration and time dependent decrease of CD33 as early
as 6 h after to 40 nM DU325 treatment with 2-fold decrease (p < 0.001) detected by qRT-PCR (Figure 4A).
The percentage of CD11b cells was followed by flow cytometry in order to monitor the size and
granularity of the cells at single cell resolution. The induction of CD11b positive cells proportional to the
maturation of HL-60 started from 5% (24 h to 40 nM DU325, p < 0.01) and reached a plateau at 90% (72 h
200 nM DU325, p < 0.001) (Figure 4B and Figure S3). Next, we followed the fate of HL-60 cells, whether
the differentiation leads to granulocytic or monocytic direction. The FSC-SSC (FSC = Forward scatter,
SSC = Side scatter) dot plots showing increasing granularity supported the granulocytic differentiation
(Figure S3). In order to clarify the result of maturation MPO (myeloperoxidase) activity, a marker of
neutrophil granulocytes was measured after 48 h treatment with DU325. The differentiating agent
DU325 at 200 nM resulted in the elevation of MPO activity 4757 ± 205 vs. (versus) untreated 3335 ±
363 U/mg protein (p < 0.01) with a maximum of 6405 ± 901 U/mg protein (5 µM) (p < 0.01) (Figure 4C).
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Figure 4. DU325 induces differentiation of HL-60 promyelocytes. As a proof of cellular differentiation,
the expression of AML blast and leukemia stem cell marker CD33 decreased (A). Matured myeloid
cell marker CD11b elevated on the cell surface detected by flow cytometry (B). Due to maturation,
the myeloperoxidase (MPO) activity of HL-60 cells increased upon treatment after 48 h (C). Cells were
assayed as described in the Materials and Methods Section 4.12.4. for CD33 and CD11b immunostaining,
and 4.11. for the MPO activity. Data are shown as arithmetic mean values ± standard deviation from
triplicate experiments. Statistical significance was calculated in relation to untreated cells and set to
** p < 0.01, *** p < 0.001.
2.3. Differentiation of HL-60 Cells Is Followed by Apoptotic Cell Death
The cytotoxic effect of DU325 on HL-60 cells was published with IC50: 66 nM (half maximal
inhibitory concentration) and the effect relied on apoptosis not necrosis confirmed by the exclusive
AnnexinV/propidium iodide staining [21]. Since Doyle at al. published earlier that induction of
differentiation of HL-60 cells is accompanied by apoptotic cell death [57], we further elucidated the
effect of DU325 on the viability of HL-60 cells. The RealTime-Glo™ MT Cell Viability Assay detects the
reduction of Nanoluc® substrate by metabolic active cells [58], it revealed that albeit DU325 negatively
affects cell viability, this is an asynchronous process not causing a simultaneous cell death in all cells
(Figure 5A). The luminescent signals (cps = count per seconds) of metabolically active cells to 1 µM
DU325 treatment were 3.31 × 104 vs. 5.27 × 104 untr. (untreated) after 24 h (p < 0.001); 3.4 × 104 vs.
1.114 × 105 untr. after 48 h (p < 0.001); 2 × 104 vs. 1.64 × 105 untr. after 72 h (p < 0.001). The decrease of
the mitochondrial membrane potential (MMP) was measured by the JC-1 assay. The early treatment
with 5 µM DU325 induced a moderate depolarization of the mitochondria in 14.2 ± 0.9 % of cells vs. in
7.5 ± 1.1 untreated (steady state) cells after 4 h (p < 0.01) (Figure 5B and Figure S4). The disturbance
of the mitochondrial homeostasis was shown after 24 h by the increase of cells with depolarized
mitochondria in 21, 43, 44, and 66% of the cells treated with 40 nM, 200 nM, 1 µM, and 5 µM DU325,
respectively (p < 0.001) (Figure 5B and Figure S4). Next, we studied that the cell death following the
differentiation of HL-60 cells is caspase-dependent or independent. We assayed the percentages of
cells bearing cleaved active caspase-3 by flow cytometry and showed a gradual increase on a dose
and time dependent manner (Figure 5C and Figure S5). After 24 h of administration of 1 µM or 5 µM
DU325 induced the percentage of active caspase-3 positive cells at peaks 44.6 ± 0.23 (p < 0.001) or 49.7
± 1.13 (p < 0.001) vs. untreated 7.5 ± 0.21. The substrate of caspase-3, Z-DEVD-aLuc was cleaved
by the lysates of HL-60 cells treated with 200 nM DU325 measured as 2227 ±156 vs. 948 ± 45 cps
untr. (p < 0.001) after 24 h (Figure 5D). The distribution of cell cycle phases and the percentages of
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hypodiploid cells, as a final stage of apoptosis with the internucleosomal degradation of the DNA
was measured by flow cytometry. The ModFit software was used for gating on the intact cells in the
FL2-A/FL2-W dot plots and for the quantitation of the percentages of cells in different cell cycle phases.
Our drug candidate led to the accumulation of cells in G2/M at the expense of G0/G1 in the case of
200 nM (12.6 ± 0.67 %, p < 0.001) and 1 µM (11.2 ± 1.52 %, p < 0.001) treatment vs. untreated (4.2 ± 0.05
%) (Figure 5E and Figure S6). The highest concentration applied, 5 µM DU325 reduced the percentages
of cells in the S-phase (17.06 ± 1.59 vs. 32.5 ± 0.13 untreated, p < 0.001) parallel with the accumulation of
G2/M (16.9 ± 0.49 vs. 4.2 ± 0.05 untreated, p < 0.001) (Figure 5D). The sub-G1 population with degraded
DNA, as a final apoptotic step, increased in a concentration and time dependent manner with 21.97 ±
0.97 % (200 nM, p < 0.001), 37.63 ± 1.04 % (1 µM, p < 0.001), 42.3 ± 1.13 % (5 µM, p < 0.001) vs. untreated
(6.2 ± 0.66 %), respectively (Figure 5F). Finally, the leakage of the LDH (lactate dehydrogenase) into the
supernatant was measured as a sign of compromised plasma membrane integrity of late apoptotic
cells [59]. We could detect LDH in the media even after treatment with 40 nM DU325 (2.6-fold increase,
p < 0.01) for 72 h (Figure 5G).
Figure 5. Differentiation of promyelocytic leukemia cells is followed by apoptotic cell death.
Differentiation of HL-60 cells was accompanied by cell death detected by RealTime-GloTM MT Cell
Viability Assay (A). The depolarization of the mitochondrial membrane potential (MMP) (B), activation
of caspase-3 (C), and the cleavage of Z-DEVD-aLuc (D) were observed after 24 h. Cell cycle was
arrested in G2/M detected after 72 h incubation (E). Finally, as a proof of massive cell death, we showed
both the appearance of the hypodiploid apoptotic cells in the sub-G1 population (F) and the leakage of
the lactate-dehydrogenase (LDH) into the supernatant (G) after 72 h incubation. Data are shown as
arithmetic mean values ± standard deviation from triplicate experiments. Statistical significance was
calculated in relation to untreated cells and set to * p < 0.05, ** p < 0.01, *** p < 0.001.
2.4. DU325 Induces Differentiation and Apoptosis of Human Primary AML Cells
Although HL-60 cells serve as a popular model of human AML in thousands of publications until
now, these cells bear the limitations of cell line models such as lab to lab variations caused by genetic
drift (HL-60 cell are cultured ex vivo from 1977), possible infection with Mycoplasma and maximum
representing only one, the host patient’s condition. In order to validate the differentiating effect of our
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imidazo[1,2-b]pyrazole-7-carboxamide derivative on AML cells, human primary bone marrow aspirate
cells were treated from patients diagnosed with AML. Here, we addressed to demonstrate two case
studies of human AML cells treated ex vivo, because both the pharmacodynamics and pharmacokinetics
of DU325 should be clarified during future pre-clinical studies to design in vivo experiments.
The percentage of CD33 positive human ‘AML1’ patient-derived bone marrow aspirate cells
dropped from 86% to 30.6 ± 0.7, (p < 0.001) and the percentage of CD11b cells increased from 4% to
12.6 ± 1.4, p < 0.05) upon 200 nM DU treatment for 48 h (Figure 6A,B).
Figure 6. The human ‘AML1’ patient-derived bone marrow aspirate cells responded to DU325 with
differentiation-coupled apoptosis. The loss of the percentage of CD33 positive and an increase of CD11b
positive cells were assayed by flow cytometry (A) and (B) after 48 incubation with 200 nM DU325.
The median fluorescent intensity (MFI) proportional with CD33 expression on the cells also decreased
by 200 nM DU325 (C) and (D). The resazurin viability assay determined IC50 value of DU325 on
the primary human patient-derived ‘AML1’ cells after 72 h treatment of 80.6 nM. Concentrations of
DU325 were as follows, 3 µM, 1µM, 333 nM, 111 nM, 37 nM, and 12 nM (E). The combined Annexin V
and propidium iodide (AnnV/PI) flow cytometry staining showed an increase of both AnnV+/PI- early
and AnnV+/PI+ late apoptotic cells after treatment with 200 nM DU325 for 48 h (F). Data are shown as
arithmetic mean values ± standard deviation. Statistical significance was set to *** p < 0.001.
The density of CD33 marker on the ‘AML1’ cells showed 65% reduction (p < 0.001) after treatment
with DU325 detected by flow cytometry (Figure 6C,D). Similarly to the HL-60 cell line, the viability
of human primary ‘AML1’ cells was hampered by DU325, with 80.6 nM IC50 value (Figure 6E).
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Differentiation-coupled apoptosis was detected by AnnV/PI (Annexin V/propidium iodide) flow
cytometry staining showing 63.5 ± 0.28 % late apoptotic AnnV+/PI+ cells vs. 16.4 ± 0.62 % untreated
after 200 nM DU325 administration for 48 h (Figure 6F).
In order to further explore the effect of DU325, cells of another case of human primary AML,
the ‘AML2’ were treated and analyzed by single cell resolution mass cytometry. The multiparametric
immunophenotyping was carried out by the simultaneous labeling with fifteen metal-tag labeled
antibodies. The number of singlets (single cell events) analyzed by CyTOF (cytometry by time-of-flight)
were as follows, 380,906 for untreated; 358,557 for 40 nM DU325 treated; and 309,345 for 200 nM
DU325 treated. The viability of ‘AML2’ cells was assessed by the uptake of 195Pt cisplatin analyzed
by CyTOF. The imidazo[1,2-b]pyrazole-7-carboxamide derivative, DU325 reduced the viability of
patient derived ‘AML2’ cells from 86.27 to 62.18% applied at 200 nM for 48 h (Figure S7). Markers of
AML such as CD7 (T-cell Leukemia Antigen), CD33, CD206 (mannose receptor C type 1, MRC1),
and CD38 (ADP-Ribosyl Cyclase 1) were included in the antibody panel. The percentage of these
subpopulations was determined by manual gating (Figure 7A) and visualized on a radar plot (Figure 7B).
The most potent effect of DU325 was at 200 nM decreasing the following subpopulations of CD7+
cells from 71.17 to 37.31%, CD33+ cells from 88.29 to 59.63%, CD7+/CD33+ cells from 66.9 to 30.38%,
CD206+ cells from 71.45 to 35.39%, and CD38bright 80.33 to 47.12% (Figure 7A,B). The trajectories
of the radar plot delineate the expression profile of the markers of the patient-derived AML2 cells
treated by 40 nM, 200 nM DU325 or left untreated. The percentage of the AML2 cells gated by the
following markers; CD45, CD11b, CD38 (all), CD163, CD11c, HLA-DR, CD16, CD19, CD66, CD14,
CD3, and CD36 upon 40 nM or 200 nM DU325 treatment is shown in Figure S8. The median metal
intensity values proportional with the expression intensities of the proteins on the singlets were as
follows; for CD7: 91.69, 75.82, and 12.08; CD33: 123.69, 93.09, and 36; CD206: 33.35, 26, and 13.24,
CD38: 843.14, 655.18, and 306.7 as untreated, 40 nM or 200 nM DU325 treated, respectively (Figure 7C).
Taken together, we could detect at single cell resolution by mass cytometry that both CD7+, CD33+,
CD7+/CD33+, CD206+, and CD38bright human primary bone marrow aspirate cells were the most
sensitive to the ex vivo treatment with our drug candidate DU325.
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Figure 7. The percentage of CD7+, CD33+, CD7+/CD33+, CD206+, and CD38bright human AML2,
patient-derived bone marrow aspirate cells decreased after the treatment with DU325 ex vivo.
Mass cytometry was used for multiparametric immunophenotyping of AML2 patient-derived cells
treated by DU325 for 48 h. Gating strategy is presented to define single cells and sub-populations of AML
cells (A). Gating strategy for 11 additional subpopulations can be found in Figure S8. The pentagram of
the population trajectories (B) shows the decrease of the percentages of CD7+, CD33+, CD7+/CD33+,
CD206+, and CD38bright AML2 cells treated with 40 nM (orange) or 200 nM DU325 (green) ex vivo
for 48 h. The overlay of the histograms demonstrates the lower expression of CD7, CD33, CD206,
and CD38 followed by DU325 treatment in nanomolar range (C).
The t-distributed stochastic neighbor embedding (tSNE) algorithm enables the multidimensional
analysis of the cells simultaneously taking into account all of fifteen antibodies in the antibody panel
for each event at single cell resolution. The cell relatedness of cells with common marker expression
is shown by the proximity of these cells in the islands of the visualization of stochastic neighbor
embedding (viSNE) graphs. The coloration is proportional to the expression intensity (blue = low, red =
high) for each marker separately [60]. This unsupervised analysis verified that CD7+, CD33+, CD206+,
and CD38 bright cells were the most sensitive to DU325 and these cells represent partially overlapping
subpopulations of AML2 human primary bone marrow aspirate cells (Figure 8). The tSNE analysis
of the other eleven markers of the antibody panel showed strong HLA-DR expression, CD45 dim
positivity, and weak CD11c+ intensity, with almost the absence of CD163+, CD11b+, CD66+, CD36+,
CD16+, CD14+, CD19+, and CD3+ populations (Figure S9).
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Figure 8. The most sensitive cells to DU325 treatment were CD7+, CD33+, CD206+, and CD38 bright.
The multidimensional viSNE plots of mass cytometry experiments illustrate the expression intensity of
CD7, CD33, CD206, and CD38 markers showing a partial overlay, common marker expression of these
subpopulations of human AML2 patient-derived cells. The coloration is proportional to the expression
intensity (blue = low, red = high). The AML2 cells were treated with 40 nM or 200 nM DU325 ex vivo
for 48 h. The viSNE plots of the rest, the other 11 markers can be found in Figure S9, the list of all
antibodies used for mass cytometry can be found in Section 4.13.
2.5. DU325 Treatment Ex Vivo Reduced Both Monocytic and Granulocytic Splenic MDSCs from the
4T1 Murine Breast Cancer Model
We have previously reviewed the contribution of MDSCs to the tumor microevolution [23,28]
and showed the expansion of these immature myeloid cells in the spleen of 4T1 breast cancer bearing
mice [29]. Here, we addressed to investigate the effect of DU325 treatment on the viability of
these MDSCs ex vivo. The resazurin viability assay showed three times sensitivity of splenocytes
from 4T1 tumor bearing mice with 70.64 nM IC50 value compared to naive cells (IC50: 221.9 nM)
(Figure 9A). The percentage of late apoptotic (AnnV+/PI+) cells from tumor-bearing mice increased
upon DU325 treatment to 31 ± 1.6% vs. 7.6 ± 3.7% (p < 0.001) untreated, and it was a significant increase
also compared to DU325 treated naive splenocytes with 17.08 ± 4.6% (p < 0.001) (Figure 9B). After the
incubation with DU325 both monocytic CD11b+/Ly6C+ and granulocytic CD11b+/Ly6G MDSCs were
reduced to six times less percentage (p < 0.001). The gating strategy for monocytic CD11b+/Ly6C+ and
for granulocytic CD11b+/Ly6G MDSCs can be found in Figure S10 and in Figure S11, respectively.
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Figure 9. DU325 treatment hampered the viability of splenocytes, both CD11b+/Ly6C+ and
CD11b+/Ly6G+ splenic MDSCs. Cells were treated with 5 µM, 1 µM, 200 nM, 40 nM, and 20 nM
DU325 for 72 h and assayed by the resazurin viability test (A). The percentage of AnnV+/PI+ late
apoptotic cells was increased after treatment with 200 nM DU325 for 72 h (B). The immunofluorescent
staining showed a reduction of both monocytic CD11b+/Ly6C+ and granulocytic CD11b+Ly6G+
MDSCs treated with 200 nM DU325 for 72 h ex vivo (C). Data are shown as arithmetic mean values ±
standard deviation from triplicate experiments. Statistical significance was set to *** p < 0.001.
3. Discussion
Multi-target drugs changing cancer cell homeostasis via modulating apoptotic, differentiation,
and metabolic pathways have been applied to treat different malignancies [61]. However, novel
agents acting via different mechanisms were approved by the FDA to manage AML and have
been recently reviewed [8,62], the overall survival of AML remained poor, especially in the elderly.
Another pathophysiologic condition is the expansion of immature myeloid cells, such as MDSCs with
potent immunosuppression in solid malignancies. We have previously reviewed the inventory of
drugs targeting these MDSCs and discussed differentiation induction therapy as an already proved
concept by the administration of vitamin D3 or ATRA [28]. However, reducing MDSCs as a part of
supportive immunotherapy still is not implemented in the clinical routine. Along SAR optimization
we have designed and synthetized a 74 member library of imidazo[1,2-b]pyrazole-7-carboxamides
with apoptotic effect on HL-60 cells [20,21]. In order to elucidate the mechanism of action and target
immature myeloid cells of AML or MDSCs, our lead imidazo[1,2-b]pyrazole-7-carboxamide derivative,
DU325 was tested on HL-60 or human primary AML bone marrow aspirate cells, or on the viability of
murine 4T1 breast cancer-derived splenic MDSCs ex vivo.
Using the HL-60 model cell line, we showed that DU325 drives early survival signals.
The percentage of pERKbright positive cells (phosphorylation of ERK1/2 at Thr202/Tyr204) was
increased after 2 h of treatment with DU325 (Figure 10). In agreement with this, the involvement
of ERK1/2 phosphorylation in cell growth and myeloid differentiation was previously published by
others upon administration of ATRA [36], G-CSF and M-CSF [39], or Xenospontine [40]. There was
an increase in the percentage of antiapoptotic Bcl-xlbright cells in line with previous reports showing
ERK dependent survival of Bcl-xlbright HL-60 cells [41,42]. The inhibition of apoptosis or the early cell
survival was accompanied with the increase of pAktbright (Ser473) HL-60 cells after DU325 treatment,
which is known to contribute to the NF-κB-driven induction of Bcl-xl [43]. Next, we investigated
the accumulation of the hematopoietic cell specific Vav1 protein, one of the master regulators of
myeloid leukemia cell differentiation [37]. The Vav1 coordinates cellular maturation via its versatile
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functions such as GEF activity, affecting cell motility, and morphology via influencing reorganization
of actin cytoskeleton and modulating gene expression via interacting with transcription factors,
ribonucleoprotein complexes [45,63]. We showed the accumulation of both Vav1 and p174-Vav1
(Tyr174) in the cytoplasm and nuclei and that was associated with changes in gene expression of
AP-1 TF complex leading to increased granularity and loss of CD33 expression. It has been known that
both ERK1/2 [51,52], and Vav1 can affect AP-1 expression [53,54]. The expression of the members of
AP-1 TF complex: FOS, JUN, JUNB, and JUND were gradually increased after DU325 stimulation.
The expression of other transcription factors was investigated such as Spl1 (Transcription factor
PU.1), RUNX1 (Runt-related transcription factor 1), CEBPA (CCAAT/enhancer binding protein alpha),
GABP1 (GA-binding protein subunit beta-1), and IRF1 (Interferon regulatory factor-1), but these
were not differentially expressed upon DU325 treatment. Brugnoli et al. found that Vav1 can be
recruited to the promoter to drive the expression of CD11b [48], and both the members of AP-1 TF
may play in the subsequent steps driving cellular differentiation. However, we did not addressed
chromatin immunoprecipitation (ChIP) to isolate target genes of AP-1 TF or Vav1 ribonucleoprotein
complexes, as we focused on the interrogation of DU325 caused phenotypic changes at single cell
level. Differentiated HL-60 cells increased their granularity detected on SSC-FSC dot plots, remained
nonadherent and short lived, decreased CD33 and increased CD11b level and MPO activity suggesting
granulocytic differentiation. The HL-60 cells poorly, only in 5% express CD34 that is why it was not
monitored [64]. The proposed role of the survival pathways (ERK phosphorylation, Bcl-xl induction,
and Akt phosphorylation) in the induction of Vav1 and AP-1 is the guidance and orchestration of
cellular differentiation of the studied immature myeloid cells (Figure 10) [65,66].
Figure 10. The series of events followed after the treatment of HL-60 cells with DU325. We obtained
ERK phosphorylation as an early survival response to treatment followed by the increase of the
percentage of the Bcl-xlbright and pAktbright cells. The induction of Vav1, pVav1, and the AP-1 complex
is a driver of cellular differentiation; FOS, JUN, JUNB, and JUND were elevated on a concentration and
time-dependent manner. As a proof of granulocytic differentiation, the cells remained nonadherent and
the expression of CD33 decreased; the granularity, CD11b expression, and MPO activity of HL-60 cells
increased upon treatment. Finally, viability of HL-60 cells was hampered shown by the depolarization
of mitochondria, activation of caspase-3, G2/M cell cycle arrest, appearance of the sub-G1 population,
and the leakage of the lactate-dehydrogenase into the supernatant.
Finally, differentiation-induced apoptosis was assayed on HL-60 cells upon DU325 administration
because it was previously published that maturation of HL-60 cells spontaneously leads to apoptosis in
these cells [55,57,67]. Maianski et al. published that the major role of the mitochondria of the matured
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neutrophils is to drive the apoptotic cell death [68]. Indeed, we showed the loss of viability in a
real-time assay and the depolarization of the mitochondria driving the intrinsic pathway of apoptosis.
Additionally, we showed the subsequent steps of apoptosis, activation of caspase-3, cleavage of
Z-DEVD-aLuc, increase of hypodiploid sub-G1 population, and leakage of LDH into the supernatant
after 72 h of treatment (Figure 10). The effect of DU325 was dissected in HL-60 cells bearing c-myc
proto-oncogene amplification as a canonic model of human AML cells [11].
We have further investigated human primary bone marrow aspirate cells form different AML
patients, as two different case studies, because the AML sub-types greatly vary regarding the genetic
mutations. The treatment of primary AML cells was performed ex vivo. However, we could
show the loss of CD33 and increase of CD11b on AML1 cells followed by apoptosis with 80.6 nM
IC50 value. The response of patient-derived AML2 cells was monitored by that state-of-the-art
single cell mass cytometry providing multiplex immunophenotyping and complex bioinformatic
analysis. Performing immunostaining with 15 antibodies revealed the most sensitive subpopulations
to DU325 treatment, namely, CD7+, CD33+, CD7+/CD33+, CD206+, and CD38bright shown by manual
gating and unsupervised viSNE analysis. The CD7, CD33, and CD38 are well-known therapeutic
targets of AML [69–71]. Although the mannose receptor C type 1 (MRC1), the CD206 has been
described as a marker of M2, alternatively polarized macrophages or M2-like monocytes with the
co-expression of CD14 and CD163 [23], we detected CD206 cells distinct from CD14+ and CD163+
cells as it shown in the viSNE maps. Using single cell RNA sequencing and Cancer Genome Atlas data
of 179 AML patients, Galen et al. found that higher expression of CD206+ was correlated with poor
survival offering CD206 as a good target in AML [72].
Based on our results and on the fact that differentiation of immature APL or AML cells increase
the sensitivity to chemotherapeutic drugs [73,74] novel studies should be initiated to examine the
efficacy of the combination of differentiating agents with existing anticancer drugs.
Another pathologic condition is the expansion of immature myeloid cells, such as MDSCs in the
bone marrow and tumor microenvironment of solid malignancies [75]. We have previously reviewed
the pharmaceutical drugs or therapeutic efforts for the selective ablation of these MDSCs, inhibiting
their recruitment or limiting their functions [28]. Using our imidazo[1,2-b]pyrazole-7-carboxamide
we could induce the apoptosis of both CD11b+/Ly6C+ monocytic and CD11b/Ly6G+ granulocytic
MDSCs isolated from the spleen of 4T1 tumor bearing mice. Maturation of MDSCs can be targeted not
only in tumor but in sepsis also. Due to the high mortality of sepsis there is an unmet high medical
need for novel therapies. It has been published that myeloid-derived cells emerge in septic patients
suppressing antigen-driven T cell proliferation, Th1/Th2 cytokine production contributing to higher
prevalence of nosocomial infections [76]. Monocytic MDSCs are accumulated in all septic patients
whereas granulocytic MDSCs are increased in gram positive cases [77]. It has been published that
matured MDSCs lose their inherent immunosuppressive phenotype that could solve the dormant state
of the antigen specific immune response in sepsis [78].
However, we have shown that both AML and MDSCs differentiate and dye by apoptosis after
the treatment with DU325, although these cells may differ in the underlying molecular mechanisms
of differentiation. These molecular pathways need further investigation to reveal. Taken together,
our imidazo[1,2-b]pyrazole-7-carboxamide derivative is an effective lead compound at nanomolar
range to target immature myeloid cells and it is offered for future pre-clinical studies including
pharmacodynamics, pharmacokinetics, and safety.
4. Materials and Methods
4.1. Ethical Statement
The animal experiments were performed in accordance with animal experimentation and
ethics guidelines of the EU (2010/63/EU). Experimental protocols were approved by the responsible
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governmental agency (National Food Chain Safety Office) in possession of an ethical clearance
XXIX./128/2013 (2013).
Participant informed consent was obtained prior surgical intervention. The collection of human
samples was complied with the Guidelines of the Helsinki Declaration. The isolation of human AML
cells was approved by the National Institute of Environmental Health under the 47226-7/2019/EÜIG
(2019) ethical license.
The patient AML1 (61-year-old male) was diagnosed with acute myeloid leukemia with cup-like
morphology. Laboratory tests showed that bone marrow aspirate cells were in 92% myeloid blasts and
CD117−/CD34−/D13−/CD33bright/cyMPO+/HLA_DR-/CD38+, 58% positive for CD56 and negative for
monocyte markers CD64, CD14, CD300e, and cyFXIII; negative for granulocyte markers CD15, CD16,
CD10, and CD11b; and negative for T cell markers CD4, CD7, and CD2. Cytogenetic status was the
following, karyotype: normal; FLT3: wild type; CEBPA: wild type; NPM1: insertion (4 nucleotides =
nts) in the 12th exon.
The patient AML2 (24-year-old male) was diagnosed with acute myeloid leukemia. Laboratory tests
showed that bone marrow aspirate cells were in 85% myeloid blasts, these were in 71% CD117+/CD34+
which cells were CD13+/CD33+/cyMPO+/HLA_DR+/CD38+/CD4−/CD11b− and in 84% CD7+, in 14%
CD56+, in 14% CD15+, in 12% cyFXIII+. Cytogenetic status was the following, karyotype: normal;
FLT3: wild type; CEBPA: duplication (24 nts), insertion (3 nts), point mutation (c.1119A>C), NPM1:
wild type.
4.2. Cell Culture and Isolation of Human AML Cells
The HL-60 acute promyelocytic leukemia and the mouse mammary carcinoma 4T1 cells were
purchased from the American Type Culture Collection (ATCC, Manassas, WV, USA) maintained
in Roswell Park Memorial Institute 1640 medium (RPMI-1640) 10% FCS (Gibco, Thermo Fisher
Scientific, Waltham, MA, USA) using tissue culture dishes (Corning Life Sciences, Corning, NY, USA).
The pH of the cell culture media was controlled to be between 7.2 and 7.4 prior to use. The medium
was supplemented with 2 mM GlutaMAX, 100 U/mL penicillin, and 100 µg/mL streptomycin (Life
Technologies, Carlsbad, CA, USA) before use. Cells were passed every three days and placed in a
humidified incubator at 37 ◦C 5% CO2 (Sanyo, Osaka, Japan).
The aspiration of ten ml bone marrow of AML patients from the pelvis was carried out upon
a clinical visit after the signed informed consent of the patients into EDTA Vacutainers (Beckton
Dickinson, Franklin Lakes, NJ, USA). Samples were centrifuged 1400 rpm 5 min, the supernatant was
removed. Red blood cell lysis was carried out by the incubation of cells with 5 mL ACK (0.155 M
NH4Cl, 10 mM KHCO3, 0.1 mM Na2EDTA, pH 7.3, Sigma-Aldrich) solution for 5 min. Samples were
loaded on cell strainer (70 µm in pore size) and washed by 20 mL PBS. Cells were counted using
Bürker chamber and trypan blue viability dye (Thermo Fisher Scientific) and plated for the treatment
as described in the relevant Sections of Materials and Methods.
4.3. Isolation of Murine Myeloid-Derived Suppressor Cells
Female Charles River-derivative BALB/c mice (8–10 weeks old) were purchased from Kobay Ltd.,
(Ankara, Turkey) and were injected orthotopically with 4T1 breast carcinoma cells (1.2 × 105 cells in 100
µL PBS) or sham injected with 100 µL PBS as described previously [29]. The animals had free access to
food and water. Biological replicates were analyzed separately from the naive and 4T1 tumor-bearing
mice. The weights of the spleens were as follows in the naïve; 99, 8, 13, 14, and 12 mg, and in the
tumor-bearing mice; 781, 812, 968, 1350, and 935 m. The weights of the tumors were as follows;
2523, 3037, 2064, 2877, and 1522 mg; the volume of the tumors were as follows; 1272, 1329, 650, 1573,
and 807 mm3 after 28 days from the injection. The volume of the tumor was measured by a caliper and
calculated by the following equation; D × d2 × 0.5, where D = major diameter, d = minor diameter as we
described previously for the 4T1 breast cancer model [79,80]. After euthanizing the animals, the spleens
were removed and homogenized freshly on cell strainer (70 µm pore size, Merck Millipore) using
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piston of a syringe and sterile PBS. Cells were pelleted by centrifugation 1500 rpm 5 min. The pellet
was resuspended in 5 mL ACK lysis buffer for 5 min. Samples were loaded on cell strainer (70 µm
in pore size) and washed by 20 mL PBS. Cells were counted using Bürker chamber and trypan blue
viability dye (Thermo Fisher Scientific) and plated for resazurin viability assay and immunofluorescent
staining upon treatment by imidazo[1,2-b]pyrazole-7-carboxamide derivative in RPMI-1640 media
supplemented with 10% FCS, 25 µM β-mercaptoethanol, 2 mM GlutaMAX, and 100 U/mL penicillin,
100 µg/mL streptomycin. Cells for flow cytometry were plated into nonadherent Petri dishes (Corning).
4.4. Treatment by the Imidazo[1,2-b]pyrazole-7-carboxamide Derivative, DU325
The imidazo[1,2-b]pyrazole-7-carboxamide derivative was synthetized at Avidin
Ltd. (Szeged, Hungary) as described previously [20]. The compound was DU325,
N-(4-aminophenyl)-2-(tert-butyl)-3-(tert-butylamino)-1H-imidazo[1,2-b]pyrazole-7-carboxamide,
the structure is available in the reference [21]. The compound was dissolved in DMSO at 10 mM
concentration. Dilutions for the treatment of the cells was prepared in RPMI-1640 complete cell culture
media as the concentration is described in the corresponding figure legends.
4.5. Resazurin Viability Assay
Cell viability was determined by the fluorescent Resazurin assay as described previously [81].
AML1, MDSCs cells (80,000), were seeded into 96-well plates (Corning Life Sciences) in 80 µL cell
culture media. Effect of DU325 was examined in AML1 cells in concentrations 3 µM, 1µM, 333 nM,
111 nM, 37 nM, and 12 nM in 100 µL final volume after 72 h incubation. Effect of DU325 was examined
in mouse splenocytes in concentrations 5 µM, 1 µM, 200 nM, 40 nM, and 20 nM in 100 µL final volume
after 72 h incubation. Resazurin reagent (Sigma-Aldrich) was dissolved in PBS (pH 7.4) at 0.15 mg/mL
concentration, sterile filtered (0.22 µm, Merck Millipore) and aliquoted at −20 ◦C. We applied resazurin
20 µL stock to 100 µL/well culture. After 12 h incubation at 37 ◦C 5% CO2 (Sanyo), fluorescence
(530 nm excitation/580 nm emission) was recorded on a multimode microplate reader (Cytofluor4000,
PerSeptive Biosytems). Viability was calculated with relation to untreated control cells and blank wells
containing media without cells. The IC50 values were calculated by GraphPad Prism® 5.
4.6. RealTime-GloTM MT Cell Viability Assay
The HL-60 cells (2000) were seeded into UV-C sterilized opaque 96-well plates (Tomtec, Budapest,
Hungary) in 40 µL media. RealTime-Glo™ reagent (Promega) (2X) was added according to the
instructions of the manufacturer. The effect of DU325 was examined in concentrations of 5 µM, 1
µM, 0.2 µM, and 0.04 µM in final volume 100 µL/well. We measured luminescence on a multimode
microplate reader (Victor 1430, Wallac, Perkin Elmer) corresponding to live cell number after 1 min to
register the baseline and subsequently samples were measured daily.
4.7. Z-DEVD-aLuc Caspase Assay
Cells were treated (1 × 106 HL-60 cells in 1 mL media) in 24-well tissue culture plates for 24 h
in the concentrations indicated in the graphs and assayed as described previously [82]. Briefly, after
24 h, cells and supernatants were harvested and centrifuged down (3000 rpm, 5 min, 4 ◦C, Eppendorf).
After the withdrawal of the supernatant pellet was lysed in 50 µL 1X Lysis Buffer, stock lysis buffer 5X
(250 mM HEPES, pH 7.4, 25 mM CHAPS, 25 mM DTT, Sigma-Aldrich), stored at −20 ◦C, was diluted
prior use freshly in sterile water. After resuspending the pellet, we incubated the samples on ice for
15 min. The debris were pelleted by centrifugation (13,000 rpm, 15 min, 4 ◦C, Eppendorf). We diluted
Z-DEVD-aLuc substrate (10 mM stock in DMSO, Avidin Ltd.) in 1X Assay Buffer, stock Assay Buffer
10X (200 mM HEPES, pH 7.4, 1% CHAPS, 50 mM DTT, 20 mM EDTA) was stored at −20◦C and it was
diluted prior use freshly in sterile water. The assay was run in 96-well sterile tissue culture plate in a
total volume of 100 µL, 5 µL cell lysate was added to 20 µM Z-DEVD-aLuc in 1X Assay Buffer in one
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well. Blanc samples contained no cell lysate. We incubated the 96-well plate at 37 ◦C for 1 h. The 50 µL
of samples were mixed with 50 µL of Luciferase Detection Reagent (Promega, USA) in a new black
wall 96-well microtiter plate. Luminescence was measured by multimode microplate reader (Victor
1430, Wallac, Perkin Elmer) recording counts per seconds (cps). Blanc data were subtracted from all
values. Each sample was assayed in triplicates.
4.8. LDH Assay
Cells were plated (2 × 105) in 500 µL media in 24-well tissue culture plates and treated as indicated
on the graphs. After 72 h cells and supernatants were centrifuged down (3000 rpm, 5 min, at 4 ◦C).
The 50 µL supernatant was measured to one well of the 96-well sterile microtiter plate and the LDH
reaction mixture was added (Catalyst solution and Dye solution in 1:45 ratio) in 50 µL according to the
instructions of the manufacturer (Roche, Basel, Switzerland). Blanc wells contained media instead
of supernatant. After 10 min incubation at RT we measured absorbance at 490 nm by multimode
microplate reader (Victor 1430, Wallac, Perkin Elmer). Blanc data were subtracted from all values.
Each sample was assayed in triplicates.
4.9. Quantitative Real-Time PCR (qRT-PCR)
HL-60 cells (1 × 106) were treated with DU325 in 6-well plates (Corning) in 2 mL in triplicate at
37 ◦C for 6, 12, 24, and 48 h. Cells were harvested by centrifugation. RNA was purified as described
previously [21]. The nucleic acid preparation was done by using the RNA purification kit (Direct-zolTM
RNA MiniPrep Kit, Zymo Research, Irvine, CA, USA), following the instructions of the manufacturer.
The quality and quantity of the isolated RNA were measured with NanoDrop1000 v. 3.8.1. (Thermo
Fisher Scientific, Waltham, MA, USA). Reverse transcription from 3 µg of total RNA was performed
with the High-Capacity cDNA Archive Kit (Applied Biosystems, Foster, CA, USA) in a total volume
of 30 µL according to the manufacturer’s protocol. After dilution with 130 µL of ultrapure water
(Applied Biosystems), cDNA was used as template for gene expression analysis. Quantitative real-time
PCR (qRT-PCR) was performed on the LightCycler® 96 System (Roche), using gene-specific primers
with SYBR Green protocol, as described previously [83]. Briefly, for cycling, each 10 µL PCR reaction
contained 1 µL cDNA (18.75 ng), 250 nM primers, and 5 µL qPCRBIO SyGreen Mix Lo-ROX (2x, PCR
Biosystems, London, UK). Primer sequences and accession numbers used in the study are listed in
the Table 1. The PCR protocol was as follows; enzyme activation at 95 ◦C for 2 min, 45 cycles of
denaturation at 95 ◦C for 10 s, annealing at 60 ◦C, and extension at 60 ◦C for 10 s. All the PCRs were
performed with three replicates. After amplification, the melting curve was checked to verify the
specificity of the PCR reactions. The Ct (cycle threshold) values were normalized to ACTB gene for
each time point. The presented relative gene expression ratios were calculated using the comparative
Ct method (2−∆∆CT). Fold change refers to 2−∆∆CT treated/2−∆∆CT untreated. All values were presented
as mean ± standard deviation (SD).
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Table 1. List of the primers used in the study.
Protein Product GeneSymbol
Accession
Number Forward Primer Reverse Primer
Myeloid Cell
Surface Antigen
CD33
CD33 NM_001082618.1NM_001177608.1 ctgacctgctctgtgtcctg atgagcaccgaggagtgagt
Jun
Proto-Oncogene JUN NM_002228.3 ccaaaggatagtgcgatgttt ctgtccctctccactgcaac
Fos
Proto-Oncogene FOS NM_005252.3 actaccactcacccgcagac ccaggtccgtgcagaagt
JunB
Proto-Oncogene JUNB NM_002229.2 atacacagctacgggatacgg gctcggtttcaggagtttgt
JunD
Proto-Oncogene JUND NM_005354.5 cagcgaggagcaggagtt gagctggttctgcttgtgtaaat
Actin Beta ACTB BC002409.2 attggcaatgagcggttc cgtggatgccacaggact
4.10. Purification of Nuclei and Immunochemical Analysis
Purification of nuclei from HL-60 cells was performed following a previously reported
procedure [48]. For Western blot analysis, total lysates from cells and nuclei were separated on
7.5% polyacrylamide denaturing gels and blotted to nitrocellulose membranes (GE Healthcare Life
Science, Little Chalfont, UK). The membranes were then reacted with antibodies directed against Vav1,
p174-Vav1, and Lamin B (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and against β-tubulin
(Sigma-Aldrich, St. Louis, MO, USA), incubated with peroxidase-conjugated secondary antibodies
and revealed using the ECL system (PerkinElmer, Boston, MA, USA), as previously reported [84].
The chemiluminescence-derived bands were acquired with ImageQuant™ LAS 4000 biomolecular
imager (GE Healthcare), and the densitometrical analysis was performed by means of Image Quant TL
software (GE Healthcare), the ratio of phosphorylated Vav (pVav) to Vav1 was quantitated.
4.11. Measurement of the MPO Activity
Cells were treated (1 × 106 HL-60 cells in 1 mL media) in 24-well tissue culture plates for 48 h
in the concentrations indicated in the graphs. After 48 h cells and supernatants were harvested and
centrifuged down (3000× g, 5 min, 4 ◦C, Eppendorf). After the withdrawal of the supernatant, the pellet
was fresh-frozen in liquid nitrogen. Samples were freeze-thawed in liquid nitrogen three times,
and then centrifuged. A 12 µL aliquot of the supernatant was mixed with 280 µL of phosphate buffer
(50 mM, pH 6) containing 0.167 mg/mL of O-dianisidine dihydrochloride and the reaction was started
with 10 µL of 0.03% hydrogen peroxide and assayed spectrophotometrically at 490 nm (Benchmark
Microplate Reader; Bio-Rad, Budapest, Hungary) after 90 s of shaking [85]. The MPO activity of the
samples (U/mL) was normalized to the protein content of each sample. Protein concentration (C) was
calculated according to the following equation, C protein (mg/mL) = (1.55 × A280) – (0.76 × A260) ×
D, where D means the dilution of the lysate. The normalized MPO activity (U/mg) was calculated
according to the following equation, enzyme activity (U/mL)/protein concentration (mg/mL).
4.12. Fluorescence Flow Cytometry
4.12.1. Detection of the Mitochondrial Membrane Potential (MMP)
Cells (200,000) were plated in 24-well tissue culture plates (Corning Life Sciences) and treated with
the indicated concentrations in the figures in 500 µL RPMI-1640 media with 10% FCS for 4 and 24 h.
Mitochondrial membrane potential was measured as described previously in reference [21]. After 4 and
24 h, the cells were harvested and centrifuged (2000 rpm, 5 min). The pellet was suspended and
incubated for 15 min in 5µg/mL JC-1 (5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethyl-imidacarbocyanine iodide,
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Chemodex, St. Gallen, Switzerland) in final volume 300 µL of cell culture media at 37 ◦C. Cells (2 × 104)
were acquired immediately on a FACSCalibur flow cytometer. Cells were visualized using FL2 (cells
with steady state mitochondria) (585/42 nm) and FL1 (cells with depolarized mitochondria) (530/30 nm)
channels. Data were analyzed using CellQuestTM software (CellQuest Pro v5.1, Becton Dickinson,
Franklin Lakes, NJ, USA). Bar graphs showed the percentage of FL1 positive cells visualized by
GraphPad Prism® 5.
4.12.2. Detection of Phosphatidylserine Exposure
Cells (200,000) were plated in 24-well tissue culture plates (Corning Life Sciences) and treated
with the indicated concentrations in the figures in 500 µL RPMI-1640 media with 10% FCS. After 48 h
incubation for the AML1 cells and 72 h for the murine splenocytes, the supernatants were harvested.
Cells were harvested with the corresponding supernatant and centrifuged down (2000 rpm, 5 min,
Eppendorf). The pellet was resuspended in Annexin V binding buffer (0.01 M HEPES, 0.14 M NaCl
and 2.5 mM CaCl2). Annexin V-Alexa Fluor® 488 (Life Technologies, 2.5:100) was added to the cells,
which were then kept for 15 min in the dark at room temperature. Before the acquisition, propidium
iodide (10 µg/mL, Sigma-Aldrich) was added in Annexin V binding buffer to dilute Annexin V-Alexa
Fluor® 488 5X. Cells (20,000 events) were analyzed on a FACSCalibur flow cytometer using CellQuest™
software (Becton Dickinson). The percentage of the FL1 (530/30 nm filter, Annexin V-Alexa Fluor® 488)
positive and FL3 (670 nm filter, propidium iodide) negative early apoptotic cells and FL1 positive and
FL3 positive late apoptotic cells were determined. The total apoptotic population includes both early
and late apoptotic cells. Column charts were created by GraphPad Prism® 5.
4.12.3. Cell Cycle and Sub-G1 Analysis
Cells (200,000) were plated in 24-well tissue culture plates (Corning Life Sciences) in RPMI-1640
10% FCS (Gibco) and were treated with the indicated concentrations in the figures in 500 µL media.
After 72 h the supernatant was harvested. Cells were harvested with the corresponding supernatant
and centrifuged down (2000 rpm, 5 min, Eppendorf). Pellet was resuspended in DNA binding buffer
(1 × PBS, 0.1% tri-sodium-citrate, 10 µg/mL PI, 0.1% Triton X-100, 10 µg/mL RNase A, (Sigma-Aldrich)).
After 30 min incubation at room temperature, cells (20,000 events) were acquired on a FACSCalibur flow
cytometer (Becton Dickinson), and the sub-G1 apoptotic population was analyzed on FL3 histograms
using CellQuestTM software (Becton Dickinson) gating out debris. We gated out doublets for cell cycle
analysis which was based on FL2-A/FL2-W dot plots, using ModFit software (v. 2.0, Becton Dickinson).
Column charts were created by GraphPad Prism® 5.
4.12.4. Immunofluorescence
Cells (500,000) were plated in 24-well tissue culture plates (Corning Life Sciences) in RPMI-1640
10% FCS (Gibco) and were treated with the indicated concentrations in the figures in 500 µL media.
After the incubation time presented in the graph or in the text, supernatant was harvested. Cells were
harvested with the corresponding supernatant and centrifuged down (2000 rpm, 5 min, Eppendorf).
The antibodies used for flow cytometry are listed in Table 2. Pellet was resuspended and fixed either in
3.5% PBS buffered formaldehyde (Molar Chemicals) for 10 min or resuspended in FACs-buffer (2%
FCS, (Gibco) in PBS) for native staining. Cells were washed with FACS-buffer, centrifuged down
(2000 rpm, 5 min, Eppendorf). In order to detect pERK, Bcl-xl, pAkt, and active caspase-3, separately,
the cells were permeabilized in Permeability buffer (1% FCS, 0.1% saponin (Sigma-Aldrich) in PBS pH
7.4) for 5 min. The detection of CD11b, CD33, CD45, Ly6C, and Ly5G was performed by native cell
surface staining gated on PI negative living cells. Cells were washed with FACS buffer, centrifuged
down (2000 rpm, 5 min, Eppendorf). After incubation for 1 h at 4 ◦C with the antibody(s) samples
were washed two times with FACS buffer. The secondary antibody detecting caspase-3, anti-rabbit IgG
conjugated with Alexa Fluor® 488 (Thermo Fisher Scientific) was diluted to 1:600 and incubated with
the cells for 30 min at 4 ◦C. After washing, 300 µL FACS buffer was added for acquisition with the
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FACSCalibur flow cytometer and CellQuestTM software (Becton Dickinson) acquiring 20,000 events.
The percentage of the positive cells is demonstrated in the graphs. Column charts were created by
GraphPad Prism® 5.
Table 2. List of the antibodies used for flow cytometry.
Target Host/Clone Fluorochrome Supplier, Cat.Number
Dilution in the
Assay
pERK1/2
(Thr202/Tyr204)
Mouse mAb,
4B11B69 Alexa Fluor
® 488 Biolegend, 675508 1:25
Bcl-xl Rabbit mAb, 54H6 Alexa Fluor® 488
Cell Sign. Techn.
2767 1:75
pAkt (Ser473) Rabbit mAb, D9E Alexa Fluor® 488
Cell Sign. Techn.
4071 1:50
Caspase-3 (Asp175) Rabbit polyclonal none Cell Sign. Techn.9661 1:500
Anti-rabbit (H+L) Goat polyclonal Alexa Fluor® 488
Thermo Fisher Sci.
A-11008 1:600
CD11b Mouse mAb, LT11 FITC ImmunoTools,21389113 1:20
CD33 Mouse mAb,WM53 PE-Cy5.5
Thermo Fisher Sci.
A15454 1:00
CD45 Mouse mAb,30-F11 FITC Biolegend, 103107 1:200
CD11b Rat mAb, M1/70 PE Biolegend, 101208 1:80
Ly6C Rat mAb, HK1.4 APC Biolegend, 128016 1:80
Ly6G Rat mAb, 1A8 APC Biolegend, 127614 1:330
4.13. Mass Cytometry
Mass cytometry was performed as described previously with minor modifications [29,86].
Briefly, 1.5 × 106 cells were plated in six-well plates for the treatment by 40 nM or 200 nM DU325 or left
untreated (untr.) in 2 mL RPMI 10% FCS media for 48 h. After the incubation time, three biological
replicates were harvested, pooled, and processed for mass cytometry staining. Cells were centrifuged
at 400× g for 5 min and assayed for viability by cisplatin staining (5 µM 195Pt, Fluidigm San Francisco,
CA, USA) for 3 min on ice in 300 µL PBS. Samples were diluted by 1000 µL Maxpar Cell Staining Buffer
(MCSB, 201068, Fluidigm) and centrifuged at 400× g for 5 min. The pellet was resuspended in 50 µL
MCSB and the antibody mix (Table 3) was added in 50 µL at 100X final dilution. The Maxpar® Human
Monocyte/Macrophage Phenotyping Panel Kit (201317, Fluidigm,) was used for mass cytometric
analysis (Table 3). After 45 min incubation at 4 ◦C, antibodies were washed two times by 1 mL
MCSB and centrifuged at 400× g for 5 min. The cells were suspended in the residual volume and
fixed in 1.6% formaldehyde (freshly diluted from 16% Pierce formaldehyde with PBS, Thermo Fisher
Scientific) and incubated for 10 min at 4 ◦C. Cells were centrifuged at 800× g for 5 min. The DNA
intercalator (201192A, Cell ID 191/193 Iridium, Fluidigm) was added in 125 nM in Maxpar Fix and
Perm (201067, Fluidigm) in 350 µL for overnight at 4 ◦C. Next day, the cells for the acquisition were
centrifuged at 800× g for 5 min then were washed by 2 mL MCSB and centrifuged at 800× g for
5 min. Cells were suspended in 1 mL PBS (for WB injector, 107950, Fluidigm) and counted in a Bürker
chamber during centrifugation. For acquisition, the concentration of cells was set to 0.5 × 106/mL in cell
acquisition solution (CAS, 201241, Fluidigm) containing 10% EQ Calibration Beads (201078, Fluidigm).
Cells were filtered through 30 µm gravity filter (CellTrics, Sysmex Gmbh, Bornbach, Germany) and
acquired freshly. Mass cytometry data were analyzed in Cytobank (Beckman Coulter, Brea, CA, USA).
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Viable cells and single cells were determined, viSNE (visualization of stochastic neighbor embedding)
analysis (iterations = 1000, perplexity = 30, theta = 0.5), was carried out on 5 × 104 single cell events.
Table 3. List of the antibodies used for mass cytometry.
Target Clone Metal Tag
CD19 HIB19 142Nd
CD11b ICRF44 144Nd
CD7 CD7-6B7 147Sm
CD66 CD66a-B1.1 149Sm
CD36 5-271 152Sm
CD163 GHI/61 154Sm
CD45 HI30 156Gd
CD11c Bu15 159Tb
CD14 M5E2 160Gd
CD16 3G8 165Ho
CD38 HIT2 167Er
CD206 15-2 168Er
CD33 WM53 169Tm
CD3 UCHT1 170Er
HLA-DR L243 174Yb
4.14. Statistical Analysis
Statistical analysis was performed using two-tailed, homoscedastic Student’s t-test to evaluate
the statistical significance (set at * p < 0.05, ** p < 0.01, *** p < 0.001) between two given experimental
groups: pairwise comparison of each sample to the untreated control.
5. Conclusions
The imidazo[1,2-b]pyrazole-7-carboxamide derivative, DU325 drug candidate induces
differentiation-coupled apoptosis of immature myeloid cells such as HL-60 and human patient-derived
AML cells. The sensitivity of myeloid-derived suppressor cells to DU325 was shown using MDSCs from
the murine 4T1 breast cancer model. Pathways, such as ERK1/2 phosphorylation, Bcl-xl induction and
Akt phosphorylation, accumulation of Vav1, induction of AP-1 TF complex are involved in the response
to DU325 of HL-60 cells. Maturation of HL-60 cells led to apoptotic cell death, the depolarization of
mitochondria, activation of caspase-3, and degradation of DNA. The subpopulations of CD7+, CD33+,
CD7+/CD33+, CD206+, and CD38bright were the most sensitive to DU325 treatment of human primary
AML cells.
6. Patents
The imidazo-pyrazole carboxamide derivative of the study has been patented entitled
“Imidazo-pyrazole carboxamide derivatives as anticancer agents and the synthesis thereof”, WO2019220155.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/21/14/
5135/s1. The followings are available online. Figure S1: DU325 drives survival pathways, increases pERK,
Bcl-xl, and pAkt bright cells, as an early response to treatment, Figure S2: Representative Western blots
show the accumulation of Vav1 in whole cell lysates (A) and in isolated nuclei (B) upon treatment, Figure S3:
DU325 induces the differentiation, increases the granularity and CD11b expression of HL-60 promyeloblasts,
Figure S4: DU325 induces the depolarization of the mitochondrial membrane potential (MMP), Figure S5:
DU325 treatment increased the percentage of cleaved caspase-3 positive cells, Figure S6: DU325 treatment
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increased the percentage of the hypo-diploid apoptotic cells in the sub-G1 population, Figure S7: DU325 hampers
the viability of human patient-derived bone marrow aspirate AML cells, Figure S8: Mass cytometric gating strategy
of the immunophenotyping of the human patient-derived bone marrow aspirate AML cells upon treatment by
DU325, Figure S9: The multiparametric tSNE analysis of human patient-derived AML bone marrow aspirate cells
treated by DU325, Figure S10: The CD11b+/Ly6C+ monocytic myeloid-derived suppressor cells are sensitive to
DU325 treatment, Figure S11: The CD11b+/Ly6G+ granulocytic myeloid-derived suppressor cells are sensitive to
DU325 treatment.
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